Dr. Rosenfeld was a lead investigator in the Phase 3 ARRIVAL study, sponsored by Vertex, which found Ivacaftor (KALYDECO®) is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. Dr. Rosenfeld noted “The premise of newborn screening for CF is to intervene very early in the course of disease with the goal of improving long term outcomes, so this is a significant milestone for parents and caregivers of young children with CF.”
Dr. Rosenfeld is attending physician at Seattle Children’s Hospital and Professor in the Department of Pediatrics at the University of Washington School of Medicine. Her clinical interests focus on the diagnosis and management of respiratory illnesses in children of all ages. Her research program focuses on the assessment and treatment of early cystic fibrosis (CF) lung disease, including infant and preschool lung function tests, determining risk factors for early acquisition of Pseudomonas aeruginosa and clinical trials in infants with CF.
She is also an investigator in a national network investigating rare disorders of mucociliary clearance, including primary ciliary dyskinesia. She is director of the Clinical Research Scholars Program, co-director of the Seattle Children’s Fellows College. She serves as CF consultant to the Washington State Newborn Screening Program.Source: www.seattlechildrens.org